HC Wainwright Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its price objective lifted by HC Wainwright from $600.00 to $660.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday. TD Cowen upped their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research note on Tuesday. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $586.00.

United Therapeutics Trading Up 0.8%

NASDAQ UTHR opened at $592.98 on Tuesday. The business’s 50-day moving average price is $500.92 and its 200 day moving average price is $476.29. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $607.89. The company has a market capitalization of $25.99 billion, a PE ratio of 21.25, a price-to-earnings-growth ratio of 2.12 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter in the previous year, the business earned $6.19 EPS. The firm’s revenue was up 7.4% on a year-over-year basis. Equities analysts predict that United Therapeutics will post 24.48 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,707,270.53. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,938,901.40. This represents a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 333,820 shares of company stock valued at $165,495,478. 10.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. AE Wealth Management LLC lifted its stake in shares of United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC grew its stake in shares of United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 2,975 shares in the last quarter. Optimize Financial Inc acquired a new stake in shares of United Therapeutics in the third quarter valued at about $444,000. Simplify Asset Management Inc. purchased a new stake in shares of United Therapeutics during the 3rd quarter valued at about $8,351,000. Finally, Osaic Holdings Inc. raised its holdings in shares of United Therapeutics by 271.0% during the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after buying an additional 33,662 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 Phase 3 success — The pivotal TETON‑1 study met its primary endpoint, showing a clinically meaningful FVC improvement (Hodges‑Lehmann estimate ~130.1 mL vs placebo at 52 weeks), supporting Tyvaso’s potential expansion into IPF and a likely regulatory path. BusinessWire: TETON‑1 Results
• Positive Sentiment: Wall Street upgrades and target lifts — Multiple firms raised price targets (TD Cowen, HC Wainwright, BofA, TD Cowen to ~$660 among others), reflecting materially higher revenue/market‑expansion assumptions if Tyvaso wins an IPF label. TickerReport: HC Wainwright Raise
• Positive Sentiment: Buyback / ASR and ralinepag momentum — Recent company buyback authorizations (including accelerated share repurchase activity) and positive Phase 3 ralinepag data (PAH) add to near‑term shareholder‑return dynamics and reduce share count risk. QuiverQuant: Buyback & Ralinepag
• Neutral Sentiment: Heavy call‑option activity and volume — Unusually large call buying and above‑average equity volume indicate speculative positioning and short covering; this can amplify moves short term but is not a fundamental read‑through by itself.
• Neutral Sentiment: Mixed analyst stances — Some firms raised targets but kept neutral/equal‑weight ratings (e.g., Wells Fargo, BofA), signaling differing views on how much IPF uptake and pricing convert to durable earnings. 24/7 Wall St.: Dual Target Hikes
• Negative Sentiment: Valuation and execution risk cautions — Some analysts note that strong trial momentum is partially offset by high valuation and execution/regulatory risk (commercial rollout, payer uptake), which could limit further multiple expansion. TipRanks: Balanced View
• Negative Sentiment: Large insider selling flagged — Public filings compiled by data providers show extensive insider sales over recent months; investors often view concentrated insider selling as a negative signal to monitor. QuiverQuant: Insider Activity
• Negative Sentiment: Questions about sustainability of the move — Some market commentaries (and earnings‑estimate trends) warn the post‑trial pop may not sustain unless follow‑on commercialization, label, and payer access dynamics become clearer. Zacks: Will Strength Last?

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.